Current Report Filing (8-k)
January 09 2023 - 04:32PM
Edgar (US Regulatory)
0001813814 false 0001813814 2023-01-09
2023-01-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 9,
2023
MIND MEDICINE (MINDMED) INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
British Columbia, Canada |
|
001-40360 |
|
98-1582438 |
(State or Other
Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
One World Trade Center, Suite 8500
New York, New York
|
|
|
|
10007 |
(Address of Principal Executive
Offices) |
|
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (650)
208-2454
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Shares |
|
MNMD |
|
The
Nasdaq Stock Market LLC |
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On January 9, 2023, Mind Medicine (MindMed), Inc. (the
“Company”) issued a press release (the “Press Release”) providing a
corporate update on the Company’s current product candidates and
discussing the Company’s 2023 outlook. A copy of the Press Release
is attached as Exhibit 99.1 hereto, and is incorporated by
reference herein.
Item 9.01 |
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MIND MEDICINE
(MINDMED) INC. |
|
|
|
|
Date: January 9, 2023 |
|
|
|
By: |
|
/s/ Robert Barrow
|
|
|
|
|
Name: |
|
Robert Barrow |
|
|
|
|
Title: |
|
Chief Executive Officer |
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Feb 2023 to Mar 2023
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Mar 2022 to Mar 2023